Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Christopher Viehbacher
Biotech
Biogen 'could migrate' to immunology, with $10B 'dry powder'
Long known as a neuroscience company, Biogen “could migrate” into immunology, CEO Christopher Viehbacher signaled Tuesday.
Annalee Armstrong
Apr 25, 2023 10:47am
Biogen's brand-new CEO moves immediately for pipeline rebuild
Feb 15, 2023 10:30am
Ito out at PureTech, MIT after Epstein scandal
Sep 9, 2019 5:06am
